Valor diagnóstico de segundas biopsias prostáticas en varones de riesgo. estudio estratificado por valor de psa

Deval, José Cervera; Olaya, F.J. Morales; Fayos, J. Jornet; Anon, M. Gonzalez

doi:10.1016/s0210-4806(04)73158-7

Cited by 4 publications

(1 citation statement)

References 31 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum PSA levels can also increase in prostatitis, [3, 4] and approximately 20%–30% of prostate cancers are missed when the cut-off value is set to 4 ng/mL [5–7]. The false negative rate in the first biopsy is estimated between 12% and 32% [8, 9], and a large population of men with chronically high serum PSA levels undergo repeated biopsies to eliminate the possibility of prostate cancer [3, 4]. …”

Section: Introductionmentioning

confidence: 99%

Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer

et al. 2012

View full text Add to dashboard Cite

Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (P = 0.022, Mann-Whitney U test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level.

show abstract